SCIB1: Safety Review and Dose Escalation

31 January 2011

                             Scancell Holdings Plc                             

                    (`Scancell Holdings' or the `Company')                     

                   SCIB1: Safety Review and Dose Escalation                    

Scancell Holdings Plc, (AIM: SCLP), the developer of therapeutic cancer
vaccines, is pleased to announce that the first group of patients receiving the
lowest dose of SCIB1 (its DNA ImmunoBody® vaccine being developed for the
treatment of melanoma) in the Phase I clinical trial has been evaluated by the
Cohort Review Committee. 

Following review of the safety data from the first three patients after three
treatments, the Cohort Review Committee has approved escalation of the dose and
recruitment of the next group of patients as planned. 

The trial, which commenced in June 2010, is designed to evaluate the safety and
tolerability of SCIB1 in patients with late stage melanoma and also to gather
data on the effects of SCIB1 on tumour growth and cellular immune response.

Professor Lindy Durrant, CEO of Scancell Holdings and Professor of Cancer
Immunotherapy at Nottingham University, commented: "We are pleased that the
Cohort Review Committee has given us the go-ahead to escalate the dose of
SCIB1. This initial data, combined with the recent recruitment of a fourth
trial centre at Leeds and the approval by GTAC and MHRA for recruitment of
earlier stage patients is a very encouraging development. There remains a
pressing need for safe new treatments for this devastating disease and these
developments have allowed us to make further progress towards this goal."

For further information contact:

Scancell Holdings Plc                          + 44 (0)207 245 1100
                                                                   
Professor Lindy Durrant                                            
                                                                   
Hansard Communications                         + 44 (0)207 245 1100
                                                                   
Kirsty Corcoran/Adam Reynolds                                      
                                                                   
Zeus Capital - Nominated Adviser/Joint         + 44 (0)161 831 1512
Broker                                                             
                                                                   
Ross Andrews/Tom Rowley                                            
                                                                   
Matrix Corporate Capital LLP - Joint Broker     [phone]
                                                                   
Robert Naylor/Stephen Waterman                                     

About Scancell

Scancell is developing novel therapeutic vaccines for the treatment of cancer
and infectious diseases based on its groundbreaking ImmunoBody® technology
platform. Scancell's first cancer vaccine SCIB1 is being developed for the
treatment of melanoma and has recently entered clinical trials.

Treating cancer by vaccination allows small non-toxic doses of a vaccine to be
administered to a patient, stimulating an immune response. Effective cancer
vaccines need to target dendritic cells to stimulate both parts of the cellular
immune system; the helper cell system where inflammation is stimulated at the
tumour site; and the cytotoxic T-lymphocyte or CTL response where immune system
cells are primed to recognise and kill specific cells.

A limitation of many cancer vaccines currently in development is that they
cannot specifically target dendritic cells in vivo. Several groups have
demonstrated successful vaccination by growing dendritic cells ex vivo, pulsing
them with tumour antigens and re-infusing them. However, this procedure is
patient specific, time consuming and expensive. Scancell has developed its
breakthrough patent protected ImmunoBody® technology to overcome these
limitations.

An ImmunoBody® is a human antibody or fusion protein engineered to express
helper cell and CTL epitopes from tumour antigens over-expressed by cancer
cells. Antibodies are ideal vectors for carrying T cell epitopes from tumour
antigens as they have long half-lives and can effectively target dendritic
cells via their Fc receptors, allowing efficient stimulation of both helper and
CTL responses.

The Immunobody® technology can be adapted to provide the basis for treating any
tumour type and may also be of potential utility in the development of vaccines
against hepatitis, HIV and other chronic infectious diseases.